<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p178" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_178{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_178{left:306px;bottom:30px;}
#t3_178{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_178{left:346px;bottom:30px;}
#t5_178{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_178{left:517px;bottom:30px;}
#t7_178{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_178{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_178{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_178{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_178{left:35px;bottom:777px;letter-spacing:0.31px;}
#tc_178{left:35px;bottom:748px;letter-spacing:0.11px;word-spacing:0.08px;}
#td_178{left:35px;bottom:724px;letter-spacing:0.09px;word-spacing:-1.13px;}
#te_178{left:260px;bottom:724px;letter-spacing:0.13px;word-spacing:-0.29px;}
#tf_178{left:35px;bottom:701px;letter-spacing:0.08px;}
#tg_178{left:35px;bottom:660px;letter-spacing:-0.1px;word-spacing:0.96px;}
#th_178{left:35px;bottom:632px;letter-spacing:0.08px;word-spacing:0.11px;}
#ti_178{left:35px;bottom:608px;letter-spacing:0.12px;word-spacing:0.07px;}
#tj_178{left:412px;bottom:616px;letter-spacing:-0.01px;}
#tk_178{left:435px;bottom:608px;letter-spacing:0.17px;word-spacing:0.02px;}
#tl_178{left:35px;bottom:585px;letter-spacing:0.12px;word-spacing:0.07px;}
#tm_178{left:35px;bottom:562px;letter-spacing:0.06px;word-spacing:0.12px;}
#tn_178{left:35px;bottom:539px;letter-spacing:0.02px;word-spacing:0.16px;}
#to_178{left:441px;bottom:546px;letter-spacing:-0.01px;}
#tp_178{left:464px;bottom:539px;word-spacing:0.19px;}
#tq_178{left:35px;bottom:515px;letter-spacing:0.1px;word-spacing:0.09px;}
#tr_178{left:352px;bottom:523px;letter-spacing:-0.01px;}
#ts_178{left:375px;bottom:515px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tt_178{left:35px;bottom:492px;letter-spacing:0.04px;word-spacing:-0.86px;}
#tu_178{left:35px;bottom:469px;letter-spacing:0.02px;word-spacing:0.17px;}
#tv_178{left:35px;bottom:446px;letter-spacing:0.14px;}
#tw_178{left:136px;bottom:453px;letter-spacing:-0.01px;}
#tx_178{left:158px;bottom:446px;letter-spacing:0.11px;word-spacing:-1.15px;}
#ty_178{left:35px;bottom:423px;letter-spacing:0.06px;word-spacing:-0.61px;}
#tz_178{left:35px;bottom:399px;letter-spacing:0.09px;word-spacing:0.1px;}
#t10_178{left:35px;bottom:376px;letter-spacing:-0.04px;word-spacing:0.22px;}
#t11_178{left:230px;bottom:384px;letter-spacing:-0.01px;}
#t12_178{left:253px;bottom:376px;letter-spacing:0.15px;word-spacing:0.05px;}
#t13_178{left:35px;bottom:353px;letter-spacing:0.03px;word-spacing:-0.46px;}
#t14_178{left:35px;bottom:330px;letter-spacing:0.04px;word-spacing:0.15px;}
#t15_178{left:35px;bottom:306px;}
#t16_178{left:35px;bottom:266px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t17_178{left:35px;bottom:238px;letter-spacing:0.1px;word-spacing:0.09px;}
#t18_178{left:35px;bottom:215px;letter-spacing:0.07px;word-spacing:0.12px;}
#t19_178{left:308px;bottom:215px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t1a_178{left:526px;bottom:215px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1b_178{left:35px;bottom:192px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1c_178{left:35px;bottom:168px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1d_178{left:35px;bottom:145px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1e_178{left:35px;bottom:122px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1f_178{left:35px;bottom:99px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1g_178{left:556px;bottom:106px;letter-spacing:0.61px;}
#t1h_178{left:35px;bottom:75px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1i_178{left:35px;bottom:52px;letter-spacing:0.38px;}
#t1j_178{left:56px;bottom:60px;letter-spacing:-0.01px;}
#t1k_178{left:618px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1l_178{left:618px;bottom:754px;letter-spacing:0.27px;}
#t1m_178{left:658px;bottom:754px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1n_178{left:798px;bottom:754px;}
#t1o_178{left:808px;bottom:754px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1p_178{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:-0.26px;}
#t1q_178{left:618px;bottom:707px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1r_178{left:618px;bottom:684px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1s_178{left:1032px;bottom:692px;}
#t1t_178{left:1077px;bottom:684px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1u_178{left:618px;bottom:661px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1v_178{left:618px;bottom:638px;letter-spacing:0.01px;word-spacing:-0.61px;}
#t1w_178{left:618px;bottom:614px;letter-spacing:0.1px;word-spacing:-0.57px;}
#t1x_178{left:618px;bottom:591px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1y_178{left:618px;bottom:568px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1z_178{left:618px;bottom:531px;letter-spacing:-0.07px;word-spacing:0.5px;}
#t20_178{left:618px;bottom:507px;letter-spacing:0.14px;word-spacing:-0.07px;}
#t21_178{left:1133px;bottom:514px;letter-spacing:0.1px;}
#t22_178{left:618px;bottom:484px;letter-spacing:0.13px;word-spacing:-0.32px;}
#t23_178{left:618px;bottom:460px;letter-spacing:0.03px;word-spacing:0.29px;}
#t24_178{left:618px;bottom:437px;letter-spacing:0.08px;word-spacing:-0.52px;}
#t25_178{left:846px;bottom:445px;}
#t26_178{left:890px;bottom:437px;letter-spacing:0.12px;word-spacing:-0.43px;}
#t27_178{left:618px;bottom:414px;letter-spacing:0.1px;word-spacing:0.09px;}
#t28_178{left:1014px;bottom:422px;letter-spacing:-0.01px;}
#t29_178{left:1038px;bottom:414px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t2a_178{left:618px;bottom:391px;letter-spacing:0.42px;word-spacing:-1.46px;}
#t2b_178{left:694px;bottom:398px;letter-spacing:-0.01px;}
#t2c_178{left:716px;bottom:391px;letter-spacing:0.12px;word-spacing:-1.17px;}
#t2d_178{left:618px;bottom:368px;letter-spacing:0.01px;word-spacing:-0.56px;}
#t2e_178{left:937px;bottom:375px;letter-spacing:-0.01px;}
#t2f_178{left:959px;bottom:368px;letter-spacing:-0.07px;word-spacing:-0.05px;}
#t2g_178{left:618px;bottom:344px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t2h_178{left:977px;bottom:352px;letter-spacing:-0.01px;}
#t2i_178{left:1000px;bottom:344px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t2j_178{left:618px;bottom:321px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2k_178{left:618px;bottom:298px;letter-spacing:0.16px;}
#t2l_178{left:715px;bottom:305px;letter-spacing:-0.01px;}
#t2m_178{left:738px;bottom:298px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2n_178{left:618px;bottom:275px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2o_178{left:618px;bottom:251px;letter-spacing:0.03px;word-spacing:-0.55px;}
#t2p_178{left:618px;bottom:228px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2q_178{left:618px;bottom:205px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2r_178{left:988px;bottom:213px;}
#t2s_178{left:1033px;bottom:205px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t2t_178{left:618px;bottom:182px;letter-spacing:-0.08px;word-spacing:0.27px;}
#t2u_178{left:618px;bottom:159px;letter-spacing:0.06px;word-spacing:0.31px;}
#t2v_178{left:618px;bottom:135px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2w_178{left:902px;bottom:143px;letter-spacing:-0.01px;}
#t2x_178{left:925px;bottom:135px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2y_178{left:618px;bottom:112px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2z_178{left:618px;bottom:89px;letter-spacing:0.15px;word-spacing:0.04px;}
#t30_178{left:618px;bottom:66px;letter-spacing:0.09px;word-spacing:0.09px;}
#t31_178{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_178{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_178{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_178{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_178{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_178{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_178{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_178{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_178{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s8_178{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s9_178{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts178" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg178Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg178" style="-webkit-user-select: none;"><object width="1210" height="935" data="178/178.svg" type="image/svg+xml" id="pdf178" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_178" class="t s0_178">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_178" class="t s1_178">© </span>
<span id="t3_178" class="t s0_178">(NCCN </span>
<span id="t4_178" class="t s1_178">© </span>
<span id="t5_178" class="t s0_178">), All rights reserved. NCCN Guidelines </span>
<span id="t6_178" class="t s1_178">® </span>
<span id="t7_178" class="t s0_178">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_178" class="t s2_178">NCCN Guidelines Version 4.2024 </span>
<span id="t9_178" class="t s2_178">Head and Neck Cancers </span>
<span id="ta_178" class="t s3_178">MS-37 </span>
<span id="tb_178" class="t s3_178">Follow-up/Surveillance </span>
<span id="tc_178" class="t s4_178">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="td_178" class="t s5_178">Follow-up Recommendations </span><span id="te_178" class="t s4_178">in the NCCN Guidelines for Head and Neck </span>
<span id="tf_178" class="t s4_178">Cancers). </span>
<span id="tg_178" class="t s6_178">Cancer of the Nasopharynx </span>
<span id="th_178" class="t s4_178">NPC is an uncommon cancer, however there were an estimated 120,434 </span>
<span id="ti_178" class="t s4_178">new cases and 73,482 deaths from NPC in 2022. </span>
<span id="tj_178" class="t s7_178">466 </span>
<span id="tk_178" class="t s4_178">However, there are </span>
<span id="tl_178" class="t s4_178">areas of the world afflicted with endemic disease; global incidence rates </span>
<span id="tm_178" class="t s4_178">are highest in Southeast Asia (especially southern China), </span>
<span id="tn_178" class="t s4_178">Micronesia/Polynesia, Eastern Asia, and North Africa. </span>
<span id="to_178" class="t s7_178">466 </span>
<span id="tp_178" class="t s4_178">Rates are two to </span>
<span id="tq_178" class="t s4_178">three times higher in men than in women. </span>
<span id="tr_178" class="t s7_178">467 </span>
<span id="ts_178" class="t s4_178">Among H&amp;N cancers, </span>
<span id="tt_178" class="t s4_178">endemic NPC has one of the highest propensities to metastasize to distant </span>
<span id="tu_178" class="t s4_178">sites, with about one in 10 patients having distant metastases at </span>
<span id="tv_178" class="t s4_178">presentation. </span>
<span id="tw_178" class="t s7_178">468 </span>
<span id="tx_178" class="t s4_178">However, with the use of modern radiotherapy techniques </span>
<span id="ty_178" class="t s4_178">as part of initial treatment, locoregional recurrences of endemic NPC have </span>
<span id="tz_178" class="t s4_178">become uncommon, occurring in fewer than 10% among all but the most </span>
<span id="t10_178" class="t s4_178">locally advanced patients. </span>
<span id="t11_178" class="t s7_178">469 </span>
<span id="t12_178" class="t s4_178">The NCCN Guidelines for Head and Neck </span>
<span id="t13_178" class="t s4_178">Cancers provide recommendations for the evaluation and management of </span>
<span id="t14_178" class="t s4_178">NPC that are aimed to address the risks for local, regional, and distant </span>
<span id="t15_178" class="t s4_178">disease. </span>
<span id="t16_178" class="t s3_178">Workup and Staging </span>
<span id="t17_178" class="t s4_178">The workup of nasopharyngeal cancer includes a complete H&amp;N </span>
<span id="t18_178" class="t s4_178">examination and other studies (see </span><span id="t19_178" class="t s5_178">Cancer of the Nasopharynx </span><span id="t1a_178" class="t s4_178">in the </span>
<span id="t1b_178" class="t s4_178">NCCN Guidelines for Head and Neck Cancers). These studies are </span>
<span id="t1c_178" class="t s4_178">important to determine the full extent of tumor to assign stage </span>
<span id="t1d_178" class="t s4_178">appropriately and to design radiation treatment volumes that will </span>
<span id="t1e_178" class="t s4_178">encompass all the disease with appropriate doses. Multidisciplinary </span>
<span id="t1f_178" class="t s4_178">consultation is encouraged. The 2017 AJCC staging classification (8 </span>
<span id="t1g_178" class="t s7_178">th </span>
<span id="t1h_178" class="t s4_178">edition) is used as the basis for treatment recommendations (see Table </span>
<span id="t1i_178" class="t s4_178">2). </span>
<span id="t1j_178" class="t s7_178">391 </span>
<span id="t1k_178" class="t s4_178">Epstein-Barr virus (EBV) DNA testing of plasma may also be considered </span>
<span id="t1l_178" class="t s4_178">(see </span><span id="t1m_178" class="t s5_178">Epstein-Barr Virus</span><span id="t1n_178" class="t s4_178">, </span><span id="t1o_178" class="t s4_178">below) although it has only prognostic, not </span>
<span id="t1p_178" class="t s4_178">predictive, value at present. HPV infection has been associated with NPC </span>
<span id="t1q_178" class="t s4_178">in case reports and very small case series, but the limited data regarding </span>
<span id="t1r_178" class="t s4_178">its impact on chemoradiation outcomes are conflicting. </span>
<span id="t1s_178" class="t s7_178">470-472 </span>
<span id="t1t_178" class="t s4_178">In most of </span>
<span id="t1u_178" class="t s4_178">these reports, HPV-associated NPC appear to have better local control </span>
<span id="t1v_178" class="t s4_178">and survival prognosis than NPC that are neither EBV nor HPV associated </span>
<span id="t1w_178" class="t s4_178">(“double negative”). Therefore, while routine testing for HPV in NPC is not </span>
<span id="t1x_178" class="t s4_178">recommended by the NCCN Panel, it is recognized that the absence of </span>
<span id="t1y_178" class="t s4_178">HPV or EBV association is a highly negative prognostic factor. </span>
<span id="t1z_178" class="t s8_178">Epstein-Barr Virus </span>
<span id="t20_178" class="t s4_178">Infection with EBV is an etiologic factor in the development of NPC. </span>
<span id="t21_178" class="t s7_178">473,474 </span>
<span id="t22_178" class="t s4_178">Workup for NPC may include EBV testing of the tumor itself and, in some </span>
<span id="t23_178" class="t s4_178">cases, plasma EBV DNA, particularly in the presence of nonkeratinizing </span>
<span id="t24_178" class="t s4_178">and undifferentiated histology. </span>
<span id="t25_178" class="t s7_178">475-477 </span>
<span id="t26_178" class="t s4_178">Testing methods for detection of EBV </span>
<span id="t27_178" class="t s4_178">in tumor include ISH for EBV-encoded RNA (EBER) </span>
<span id="t28_178" class="t s7_178">478 </span>
<span id="t29_178" class="t s4_178">and IHC staining </span>
<span id="t2a_178" class="t s4_178">for LMP1. </span>
<span id="t2b_178" class="t s7_178">479 </span>
<span id="t2c_178" class="t s4_178">ISH for EBER tends to be a more sensitive testing method for </span>
<span id="t2d_178" class="t s4_178">carcinomas, relative to LMP1 IHC staining. </span>
<span id="t2e_178" class="t s7_178">480 </span>
<span id="t2f_178" class="t s4_178">Real-time PCR may be used </span>
<span id="t2g_178" class="t s4_178">to evaluate EBV DNA titers in serum or plasma. </span>
<span id="t2h_178" class="t s7_178">481 </span>
<span id="t2i_178" class="t s4_178">Sensitivity and </span>
<span id="t2j_178" class="t s4_178">specificity values range from 53% to 96%, and 88% to 100%, </span>
<span id="t2k_178" class="t s4_178">respectively. </span>
<span id="t2l_178" class="t s7_178">482 </span>
<span id="t2m_178" class="t s4_178">Levels of plasma EBV DNA have been shown to be </span>
<span id="t2n_178" class="t s4_178">independently prognostic at baseline and following definitive </span>
<span id="t2o_178" class="t s4_178">chemoradiation. After induction chemotherapy, and after radiation, plasma </span>
<span id="t2p_178" class="t s4_178">EBV DNA levels are used in some centers as a means of outcome </span>
<span id="t2q_178" class="t s4_178">prognostication and residual disease monitoring. </span>
<span id="t2r_178" class="t s7_178">483-486 </span>
<span id="t2s_178" class="t s4_178">It should be noted </span>
<span id="t2t_178" class="t s4_178">as an important caveat that lack of harmonization of plasma EBV DNA </span>
<span id="t2u_178" class="t s4_178">assays has hampered development of consensus recommendations and </span>
<span id="t2v_178" class="t s4_178">incorporation into prognostic models. </span>
<span id="t2w_178" class="t s7_178">481 </span>
<span id="t2x_178" class="t s4_178">For patients with locoregionally </span>
<span id="t2y_178" class="t s4_178">confined NPC, studies have shown that high initial levels of plasma EBV </span>
<span id="t2z_178" class="t s4_178">DNA, or persistently elevated levels near or at the end of induction </span>
<span id="t30_178" class="t s4_178">chemotherapy or definitive intent RT or chemoradiation, are associated </span>
<span id="t31_178" class="t s9_178">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
